Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

Condition(s) targeted: Essential Hypertension

Intervention: olmesartan alone or in combination with hydrochlorothiazide (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Official title: A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Efficacy of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Secondary outcome: Safety and tolerability of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subject has mild to moderate hypertension

Exclusion Criteria:

- History of secondary hypertension

Pfizer Investigational Site, NT, Hong Kong

Pfizer Investigational Site, Shatin, NT, Hong Kong

Pfizer Investigational Site, Jakarta, Indonesia

Pfizer Investigational Site, Jakarta 11420, Indonesia

Pfizer Investigational Site, Jakarta 10430, Indonesia

Pfizer Investigational Site, Surabaya 60286, Indonesia

Pfizer Investigational Site, Quezon, Philippines

Pfizer Investigational Site, Singapore 119074, Singapore

Pfizer Investigational Site, Singapore 169608, Singapore

Pfizer Investigational Site, Kaohsiung 813, Taiwan

Pfizer Investigational Site, Taipei 106, Taiwan

Pfizer Investigational Site, Taipei 112, Taiwan

Pfizer Investigational Site, Bangkok 10400, Thailand

Pfizer Investigational Site, Bangkok 10700, Thailand

Pfizer Investigational Site, Chiang Mai 50200, Thailand

Pfizer Investigational Site, Bornova/Izmir 35100, Turkey

Pfizer Investigational Site, Haseki/Istanbul 34390, Turkey

Pfizer Investigational Site, Sihhiye/Ankara 06100, Turkey

Pfizer Investigational Site, S¿hhiye/Ankara 06100, Turkey

Pfizer Investigational Site, Haseki/Istanbul, 34390, Turkey

Pfizer Investigational Site, Medellin, Antioquia, Colombia

Pfizer Investigational Site, Barranquilla, Atlantico, Colombia

Pfizer Investigational Site, Cartagena, Atlantico, Colombia

Pfizer Investigational Site, Khet Rajathevee, Bangkok 10400, Thailand

Pfizer Investigational Site, Unknown, Bangkok, Thailand

Pfizer Investigational Site, Bogota, Cundinamarca, Colombia

Pfizer Investigational Site, Escobedo, Guayas, Ecuador

Pfizer Investigational Site, San Juan, Metro Manila, Philippines

Pfizer Investigational Site, Seremban, Negeri Sembilan 70300, Malaysia

Pfizer Investigational Site, Quito, Pichincha, Ecuador

Pfizer Investigational Site, Kuching, Sarawak 93586, Malaysia

Pfizer Investigational Site, Guei-Shan Shiang, Tau-Yuan Shian 333, Taiwan

Pfizer Investigational Site, Cali, Valle del Cauca, Colombia

To obtain contact information for a study center near you, click here.

Starting date: September 2005
Last updated: July 30, 2007